Rademikibart significantly reduced treatment failure and new moderate-to-severe COPD exacerbations in the Seabreeze STAT study, while Connect Biopharma said it plans to discuss a Phase 3 registrational program with the FDA.
Key Investor Takeaways
- Connect Biopharma (NASDAQ:CNTB) reported positive preliminary topline data from the 159-patient Phase 2 Seabreeze STAT COPD trial of rademikibart.
- Rademikibart reduced treatment failure by 81% through Week 4 versus placebo, reaching statistical significance with a p-value of 0.0122.
- New moderate-to-severe COPD exacerbations fell 85%, while new emergency department visits and hospital admissions for exacerbations were reduced by 100% through Week 4 versus placebo.
- Lung function showed a 70 mL greater improvement in FEV1 at Week 4 compared with placebo, although this result was not statistically significant at p=0.1607.
- Connect plans to engage with the FDA regarding a potential Phase 3 registrational development program, making regulatory feedback a key next step.
Why CNTB Stock Is in Focus
Connect Biopharma reported preliminary topline results from its randomized, double-blind, placebo-controlled Phase 2 Seabreeze STAT COPD study evaluating rademikibart following acute COPD exacerbations in patients with type 2 inflammation.
The study enrolled 159 adults with eosinophil counts of at least 300 cells/μL who had experienced an acute exacerbation. Participants received either a single subcutaneous dose of rademikibart or placebo alongside standard of care.
Rademikibart reduced the rate of the study’s primary endpoint, treatment failure, by 81% through Week 4 compared with placebo. Treatment failure included outcomes such as death, COPD-related hospital admission or readmission, emergency or unscheduled medical visits, and the need to intensify pharmacological treatment.
The treatment also produced an 85% reduction in new moderate-to-severe exacerbations and a 100% reduction in new emergency department visits and hospital admissions for new exacerbations through Week 4. Both measures reached statistical significance.
Rademikibart also significantly reduced rescue inhaler use from Week 2 through Week 7 and improved COPD symptoms at Week 2. The 70 mL greater improvement in FEV1 at Week 4 was described as clinically meaningful by the company but did not reach statistical significance.
No new safety signals were observed, and Connect said the treatment was well tolerated through the end of the study.
Why This Matters for Investors
The Phase 2 results provide clinical evidence supporting rademikibart’s potential use during the high-risk period immediately following an acute COPD exacerbation.
For investors, the primary endpoint result is particularly relevant because the study demonstrated a statistically significant reduction in treatment failure rather than relying solely on changes in symptoms or lung-function measurements.
The reductions in subsequent exacerbations, emergency department visits and hospitalizations could also strengthen the rationale for further development. However, these are preliminary Phase 2 findings from 159 participants, and the results will need to be confirmed through a larger development program.
The FEV1 finding warrants a more nuanced interpretation. While the 70 mL difference favored rademikibart and was characterized by the company as clinically meaningful, its p-value of 0.1607 means the Week 4 result did not demonstrate statistical significance.
Connect’s intention to approach the FDA about a Phase 3 registrational program now shifts attention toward whether regulators agree on a viable late-stage development pathway.
What to Watch Next
FDA feedback on the proposed Phase 3 program is the most important upcoming development. Investors can also watch for more detailed Seabreeze STAT COPD data, including the underlying event numbers behind the reported percentage reductions and additional analyses of efficacy and safety.
The design, size and endpoints of any Phase 3 study will be important in determining how Connect intends to confirm the Phase 2 findings and advance rademikibart toward a potential regulatory submission in COPD.